Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects ≥13 years of age

Vaccine

Volumn 24, Issue 47-48, 2006, Pages 6875-6885

  Diaz, Clemente ^a   Dentico, Pietro ^b   Gonzalez, Rocio ^c   Mendez, Rafael G ^d   Cinquetti, Sandro ^e   Barben, Julie L ^f   Harmon, Anna ^f   Chalikonda, Ira ^f   Smith, Jeffrey G ^f   Stek, Jon E ^f   Robertson, Andrew ^f   Caulfield, Michael J ^f   Biasio, Luigi R ^g   Silber, Jeffrey L ^f   Chan, Christina Y ^f   Vessey, Rupert ^f   Sadoff, Jerald ^f   Chan, Ivan S F ^f   Matthews, Holly ^f   Wang, William ^f   Schlienger, Katia ^f   Schödel, Florian P ^f   more..

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b UNIVERSITY OF BARI   (Italy)

^c Consultorio de Adolecencia ^*  (Colombia)

^d ST VINCENT MEDICAL CENTER   (United States)

^e Pieve di Soligo ^*  (Italy)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Sanofi Pasteur MSD   (Italy)

Author keywords

Clinical trial; Immunogenicity; Safety; Varicella vaccine; Varicella zoster virus; VARIVAX

Indexed keywords

CHICKENPOX VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHICKENPOX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; PRURITUS; SWELLING;

ADOLESCENT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHICKENPOX; CHICKENPOX VACCINE; DOUBLE-BLIND METHOD; FEMALE; HERPES ZOSTER; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; MALE;

EID: 33846340823     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.030     Document Type: Article

References (51)

1. LaRussa P. Clinical manifestations of varicella. In: Arvin A.M., and Gershon A.A. (Eds). Varicella-zoster virus: virology and clinical management (2000), Cambridge University Press, New York 206-219
2. Whitley R.J. Varicella-zoster virus. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases (2000), Churchill Livingstone, Philadelphia 1580-1586
3. McCrary M., Brown T.J., and Tyring S.K. Varicella-zoster virus (Herpes 3). In: Tyring S.K. (Ed). Mucocutaneous manifestations of viral diseases (2002), Marcel Dekker, New York 119-144
4. Meyer P.A., Seward J.F., Jumaan A.O., and Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 182 2 (2000) 383-390
5. Galil K., Brown C., Lin F., and Seward J. Hospitalizations for varicella in the United States, 1988-1999. Pediatr Infect Dis J 21 10 (2002) 931-935
6. Davis M.M., Patel M.S., and Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 114 3 (2004) 786-792
7. Muench R., Nassim C., Niku S., and Sullivan-Bolyai J.Z. Seroepidemiology of varicella. J Infect Dis 153 1 (1986) 153-155
8. Gabutti G., Penna C., Rossi M., Salmaso S., Rota M.C., Bella A., et al. The seroepidemiology of varicella in Italy. Epidemiol Infect 126 3 (2001) 433-440
9. Barzaga N.G., Roxas J.R., and Florese R.H. Varicella zoster virus prevalence in metro Manilla, Philippines. JAMA Southeast Asia Suppl (1994) 633-635
10. Venkitaraman A.R., Seigneurin J.M., Baccard M., Lenoir G.M., and John T.J. Measures of antibodies to varicella-zoster virus in a tropical population by enzyme-linked immunosorbent assay. J Clin Microbiol 20 3 (1984) 582-583
11. Ooi P.L., Goh K.T., Doraisingham S., and Ling A.E. Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 23 1 (1992) 22-25
12. Garnett G.P., Cox M.J., Bundy D.A., Didier J.M., and St Catharine J. The age of infection with varicella-zoster virus in St. Lucia, West Indies. Epidemiol Infect 110 2 (1993) 361-372
13. Beutels P., Clara R., Tormans G., Van Doorslaer E., and Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 174 Suppl 3 (1996) S335-S341
14. Diez Domingo J., Ridao M., Latour J., Ballester A., and Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17 11-12 (1999) 1306-1311
15. Fornaro P., Gandini F., Marin M., Pedrazzi C., Piccoli P., Tognetti D., et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Italian Sentinel Group on Pediatric Infectious Diseases. Pediatr Infect Dis J 18 5 (1999) 414-419
16. Gershon A.A. Chickenpox, measles, and mumps. In: Remington J., and Klein J. (Eds). Infections of the fetus and newborn infant. 5th ed. (2001), WB Saunders, Philadelphia 683-732
17. Schleiss M.R. Vertically transmitted herpesvirus infections. Herpes 10 1 (2003) 4-11
18. Krause P.R., and Klinman D.M. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 127 4 (1995) 518-525
19. Black S., Shinefield H., Ray P., Lewis E., Hansen J., Schwalbe J., et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 18 12 (1999) 1041-1046
20. Wise R.P., Salive M.E., Braun M.M., Mootrey G.T., Seward J.F., Rider L.G., et al. Postlicensure safety surveillance for varicella vaccine. JAMA 284 10 (2000) 1271-1279
21. Seward J.F. Update on varicella. Pediatr Infect Dis J 20 6 (2001) 619-621
22. Vessey S.J., Chan C.Y., Kuter B.J., Kaplan K.M., Waters M., Kutzler D.P., et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr 139 2 (2001) 297-304
23. Li S., Chan I.S., Matthews H., Heyse J.F., Chan C.Y., Kuter B.J., et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 21 4 (2002) 337-342
24. Takahashi M. Effectiveness of live varicella vaccine. Expert Opin Biol Ther 4 2 (2004) 199-216
25. Kuter B., Matthews H., Shinefield H., Black S., Dennehy P., Watson B., et al. Ten-year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23 2 (2004) 132-137
26. Nguyen H.Q., Jumaan A.O., and Seward J.F. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352 5 (2005) 450-458
27. Centers for Disease Control and Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996;45(RR-11):1-36.
28. American Academy of Pediatrics. Varicella zoster infections. In: 2003 Red Book: Report of the Committee on Infectious, Diseases, Elk Grove Village, IL: American Academy of Pediatrics, 2003:672-686.
29. Arbeter A.M., Starr S.E., and Plotkin S.A. Varicella vaccine studies in healthy children and adults. Pediatrics 78 4 Pt 2 (1986) 748-756
30. Gershon A.A., Steinberg S.P., and Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics 78 4 Pt. 2 (1986) 757-762
31. White C.J., Kuter B.J., Hildebrand C.S., Isganitis K.L., Matthews H., Miller W.J., et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987-1989. Pediatrics 87 5 (1991) 604-610
32. Kuter B.J., et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Vaccine 13 11 (1995) 967-972
33. Ampofo K., Saiman L., LaRussa P., Steinberg S., Annunziato P., and Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 34 6 (2002) 774-779
34. Kosuwon P., Wasi C., Sutra S., Kositanont U., Hutagalung Y., and Bock H.L. Flexibility in the administration schedule of varicella vaccination in healthy adolescents and young adults. Asian Pac J Allergy Immunol 20 4 (2002) 241-245
35. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 22 (2005) 2271-2284
36. Lau Y.L., Vessey S.J., Chan I.S., Lee T.L., Huang L.M., Lee C.Y., et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine 20 23-24 (2002) 2942-2949
37. Henderson F., Reisinger K., Malacaman E.A., Levin M.J., Bromberg K., Dennehy P., et al. Dose response trend of process upgrade varicella vaccine (PUVV) in concomitant use with M-M-R™II in healthy children. Proceedings of the 22nd annual meeting of the European society for pediatric infectious diseases. Tampere, Finland, May 26-28 (2004)
38. Block B.L., Henderson F., Malacaman E., Dennehy P.H., Chartrand S.A., Waters M., et al. Safety and tolerability of high-potency process upgrade varicella vaccine (PUVV) compared with VARIVAX™ in healthy children. Proceedings of the 22nd annual meeting of the European society for pediatric infectious diseases. Tampere, Finland, May 26-28 (2004)
39. Mendez R., Henderson F., Reisinger K., Malacaman E., Harmon A., Waters M., et al. Immunogenicity and safety of process upgrade varicella vaccine (PUVV) with new stabilizer as compared to PUVV with current stabilizer when administered concomitantly with M-M-R™II in healthy children. Proceedings of the 22nd annual meeting of the European society for pediatric infectious diseases. Tampere, Finland, May 26-28 (2004)
40. Wasmuth E.H., and Miller W.J. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 32 3 (1990) 189-193
41. Provost P.J., Krah D.L., Kuter B.J., Morton D.H., Schofield T.L., Wasmuth E.H., et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 9 2 (1991) 111-116
42. Smith J.G., Liu X., Kaufhold R.M., Clair J., and Caulfield M.J. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 8 5 (2001) 871-879
43. Levin M.J., Smith J.G., Kaufhold R.M., Barber D., Hayward A.R., Chan C.Y., et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. J Infect Dis 188 9 (2003) 1336-1344
44. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 2 (1985) 213-226
45. Mehrotra D. Improving the Brown-Forsythe solution to the generalized Behrens-Fisher problem. Commun Stat Simul Comput 23 (1997) 1139-1145
46. Brown M.B., and Forsythe A.B. The small sample behavior of some statistics which test the equality of several means. Technometrics 16 (1974) 129-132
47. Abendroth A., and Arvin A.M. Host response to primary infection. In: Arvin A.M., and Gershon A.A. (Eds). Varicella-zoster virus: virology and clinical management (2000), Cambridge University Press, New York 142-146
48. Skull S.A., and Wang E.E. Varicella vaccination-a critical review of the evidence. Arch Dis Child 85 2 (2001) 83-90
49. Watson B. Varicella: a vaccine preventable disease?. J Infect 44 4 (2002) 220-225
50. White C.J., Kuter B.J., Ngai A., Hildebrand C.S., Isganitis K.L., Patterson C.M., et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 11 1 (1992) 19-23
51. Gershon A.A., Steinberg S.P., LaRussa P., Ferrara A., Hammerschlag M., and Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 158 1 (1988) 132-137